Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib

The Bruton tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side effects of ibrutinib. The second-generation Btk inhibitor acalabrutinib was developed...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Bye, Alexander P., Unsworth, Amanda J., Desborough, Michael J., Hildyard, Catherine A. T., Appleby, Niamh, Bruce, David, Kriek, Neline, Nock, Sophie H., Sage, Tanya, Hughes, Craig E., Gibbins, Jonathan M.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2017
Fag:
Lymphoid Neoplasia
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728643/
https://ncbi.nlm.nih.gov/pubmed/29296914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017011999
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker